PureTech Health plc (LON:PRTC)
130.00
+4.80 (3.83%)
Apr 28, 2026, 4:35 PM GMT
PureTech Health Revenue
PureTech Health had revenue of $1.85M USD in the half year ending June 30, 2025, a decrease of -41.24%. This brings the company's revenue in the last twelve months to $6.39M, up 1,265.60% year-over-year. In the year 2024, PureTech Health had annual revenue of $4.83M with 44.98% growth.
Revenue (ttm)
$6.39M
Revenue Growth
+1,265.60%
P/S Ratio
67.84
Revenue / Employee
$114.13K
Employees
56
Market Cap
316.44M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.83M | 1.50M | 44.98% |
| Dec 31, 2023 | 3.33M | -12.29M | -78.68% |
| Dec 31, 2022 | 15.62M | -1.77M | -10.18% |
| Dec 31, 2021 | 17.39M | 5.62M | 47.76% |
| Dec 31, 2020 | 11.77M | 1.96M | 20.00% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Avacta Group | 113.00K |
| Scancell Holdings | 4.71M |
| Oxford Biomedica | 168.74M |
| Bioventix | 12.54M |
| Faron Pharmaceuticals Oy | 1.14M |
| Oxford Nanopore Technologies | 223.90M |
| 4basebio | 1.78M |
| Ondine Biomedical | 1.18M |
PureTech Health News
- 1 day ago - PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors - Business Wire
- 6 days ago - Positive Phase 1b Results for PureTech Health (PRTC) - GuruFocus
- 6 days ago - PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML) - Business Wire
- 15 days ago - PureTech Health: Notice of Results - Business Wire
- 26 days ago - PureTech Health (PRTC) Advances Deupirfenidone for Pulmonary Fibrosis Treatment - GuruFocus
- 26 days ago - PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine - Business Wire
- 4 weeks ago - PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans - Business Wire
- 6 weeks ago - PureTech Health Transcript: Leerink Global Healthcare Conference 2026 - Transcripts